Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

InVivo Therapeutics Holdings Corp. (NVIV) Reports Positive Results of New Spinal Cord Injury Treatment on Rodents

|Includes: InVivo Therapeutics Holdings Corp (NVIV)

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (NYSE:SCI), today announced that preliminary data revealed that their proprietary biopolymer scaffold implant demonstrated positive therapeutic results with rodents. Following the implementation of the Company’s technology in an acute SCI model, the data showed evidence of decreased scarring, decreased lesion size, and increased neural survival. These results reinforce previous positive data from Invivo’s findings in hemisection models in both rodents and non-human primates.

The major cause of SCI is motor vehicle accidents, sports-related accidents and falls. Most of the currently used treatments for SCI have focused on either the rehabilitation of patients with paraplegia to maximize the remaining functions of the upper and lower extremities or the prevention and management of complications after spinal cord injury. These management focuses have improved the quality of life for patients with SCI but treatment to regenerate the damaged spinal cord tissues and neural cells has not been standardized and no drug has yet to be effective in improving the functional and clinical status.

“We are very excited that results from the most applicable injury model to humans, the contusion model, appear to confirm our findings in the hemisection model,” said Rick Layer, PhD, Research & Development Manager at InVivo Therapeutics.

“I am looking forward to finalizing this analysis and to submitting the data to a peer-reviewed journal, as well as to presenting it at upcoming scientific meetings. These data provide further encouragement as we work with the FDA on our recently submitted application,” added Jonathan Slotkin, MD, Medical Director at Invivo Therapeutics.

For more information, please visit

Please see disclaimer on the QualityStocks website: